SCHEMBL2650902

SCHEMBL2650902

CCCOc1cc(OCc2ccccc2)cc(C(=O)OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.60
HPGD P15428 1/20 0.60
KMT2A Q03164 4/20 0.60
MEN1 O00255 3/20 0.60
MAPT P10636 3/20 0.51
RAB9A P51151 3/20 0.51
MAOB P27338 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
NR4A2 P43354 1/20 0.50
HDAC3 O15379 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC2 Q92769 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
NPC1 O15118 2/20 0.49
SMPD1 P17405 1/20 0.49
MRGPRX4 Q96LA9 2/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
GCK P35557 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391547 0.92 MEN1 (0.71) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL9167382 0.91 PLA2G2A (0.58) LMNAHPGDKMT2AMEN1NR4A2
SCHEMBL31007012 0.91 PLA2G2A (0.58) LMNAHPGDKMT2AMEN1NR4A2
SCHEMBL9323928 0.89 LMNA (0.60) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL183994 0.89 LMNA (0.70) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL2808656 0.88 LMNA (0.59) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL9323897 0.88 PLA2G2A (0.54) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL9325186 0.88 PLA2G2A (0.54) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL9324877 0.88 PLA2G2A (0.54) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL2651146 0.87 KMT2A (0.79) KMT2AMEN1MAOBSMN1; SMN2NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910350-A1 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES AstraZeneca AB (SE) 2008-04-16 EP disclosed
EP-1902052-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES AstraZeneca AB (SE) 2008-03-26 EP disclosed
EP-1891058-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES AstraZeneca AB (SE) 2008-02-27 EP disclosed
WO-2007007040-A1 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES ASTRAZENECA AB (SE) 2007-01-18 WO disclosed
WO-2007007041-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2007-01-18 WO disclosed
WO-2006125972-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2006-11-30 WO disclosed
EP-1718625-A1 COMPOUNDS AstraZeneca AB (SE) 2006-11-08 EP disclosed
EP-1697324-A1 BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS AstraZeneca AB (SE) 2006-09-06 EP disclosed
WO-2005080360-A1 COMPOUNDS ASTRAZENECA AB (SE) 2005-09-01 WO disclosed
WO-2005054200-A1 BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS ASTRAZENECA AB (SE) 2005-06-16 WO disclosed